Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ICMT | O60725 | 2/20 | 0.41 |
| ▸ | DDX3X | O00571 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17490608 | 0.90 | EPHX2 (0.46) | HDAC1CSNK2A1EPHX2GBA1HRH4 | |
| SCHEMBL17776274 | 0.90 | EPHX2 (0.46) | HDAC1CSNK2A1EPHX2GBA1HRH4 | |
| SCHEMBL21626004 | 0.90 | POLB (0.47) | HDAC1CSNK2A1EPHX2ICMTGBA1 | |
| SCHEMBL2601644 | 0.89 | HDAC1 (0.43) | HDAC1CSNK2A1EPHX2ICMTGBA1 | |
| SCHEMBL13437065 | 0.89 | FOLH1 (0.46) | HDAC1CSNK2A1EPHX2DDX3X | |
| SCHEMBL18768813 | 0.89 | EPHX2 (0.51) | HDAC1EPHX2GBA1 | |
| SCHEMBL26517333 | 0.87 | EPHX2 (0.53) | EPHX2GBA1HRH4HRH3GGPS1 | |
| SCHEMBL16234065 | 0.86 | CSNK2A1 (0.40) | HDAC1CSNK2A1EPHX2ICMTGBA1 | |
| SCHEMBL18289680 | 0.86 | CYP19A1 (0.41) | HDAC1CSNK2A1EPHX2DDX3XGGPS1 | |
| SCHEMBL21309983 | 0.86 | EPHX2 (0.44) | HDAC1CSNK2A1EPHX2GBA1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969622-B2 | Dendritic molecular intracellular transporters and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-7935782-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | VANDERBILT UNIVERSITY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090306335-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | NATIONAL SCIENCE FOUNDATION | 2009-12-10 | — | — | US | disclosed |
| US-20080221043-A1 | Guanidinium compounds for drug delivery | VANDERBILT UNIVERSITY | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221043-A1 | Guanidinium compounds for drug delivery | GMPS, GUCY1A1, GUCY1A2 | HDAC1 3605/4885CSNK2A1 2725/4885EPHX2 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.